Cercar
01/11/2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
Brandao, M, Prisciandaro, E, Xenophontos, E, Mariolo, A, Sadeghi, AH, Filippi, AR, Levy, A, Bandura, A, Caramella, C, Dickhoff, C, de Margerie-Mellon, C, Faivre-Finn, C, Portik, D, Sanchez-Lorente, D, De Ruysscher, D, Smit, E, Gobbini, E, Fadel, E, Ruffini, E, Olmetto, E, Cortiula, F, Bahce, I, Houda, I, Opitz, I, Naidoo, J, Edwards, J, Remon, J, Benitez, JC, Trujillo, JC, Derks, J, Amrane, K, Hartemink, KJ, Stathopoulos, K, Hendriks, LEL, Iglesias, M, Occhipinti, M, Guckenberger, M, Levra, NG, Girard, N, Reguart, N, Mercier, O, Bironzo, P, Hofman, P, Petersen, RH, De Angelis, R, Abgral, R, Terrisse, S, Popat, S, Pierret, T, Blum, TG, Ricardi, U, Dionisi, V, Berghmans, T, Dingemans, AMC. Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108798. PMID:41108881. IF:4.400(Q1/2D).
01/12/2025
Beyond Contraception: Exploring Health Benefits of Short-Acting Reversible Contraceptives-A Narrative Review
Perello-Capo, J, Quílez-Conde, JC, Calaf-Alsina, J. Beyond Contraception: Exploring Health Benefits of Short-Acting Reversible Contraceptives-A Narrative Review. WOMENS HEALTH REPORTS. 2025; 6(1)DOI:10.1177/26884844251405066. PMID:. IF:(Q/D).
01/10/2025
Proficiency in Laparoscopic Training: online versus Onsite Suturing Courses
Argay, I, Schettini, G, Giorgi, M, Habib, N, Rovira, R, Wattiez, A, Amro, B, Varbiro, S, Centini, G. Proficiency in Laparoscopic Training: online versus Onsite Suturing Courses. JSLS-Journal of the Society of Laparoendoscopic Surgeons. 2025; 29(4)DOI:10.4293/JSLS.2025.00084. PMID:41438213. IF:1.800(Q2/5D).
30/04/2025
CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases
González-Guerrero, L, Castellet, H, Martinez, Clara, González, N, Guijarro, F, Lloveras, N, Pratcorona, M, Gich, I, Berenguer-Molins, P, Perera-Bel, J, Zamora, L, Mascaró, M, Sampol, A, Garcia-Guiñón, A, Vives, S, Tormo, M, Arnan, M, Villamor, N, Nomdedéu, JF. CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases. Diagnostic Pathology. 2025; 20(1)DOI:10.1186/s13000-025-01655-w. PMID:40307896. IF:2.300(Q2/5D).
17/11/2025
Disease spectrum and long-term prognosis of patients with BAG3-associated neuromuscular diseases in Europe
Fernández-Eulate, G, Gitiaux, C, Thiele, S, Jungbluth, H, Potulska-Chromik, A, Marini-Bettolo, C, Davion, JB, Morís, G, Gallardo, E, Olivé, M, de la Hoz, CPD, Audic, F, Isapof, A, Walter, MC, Angelini, C, Bertini, E, Schara-Schmidt, U, Claeys, KG, Dohrn, MF, Dembele, M, Fer, F, Brochier, G, Evangelista, T, Kostera-Pruszczyk, A, Attarian, S, Straub, V, Domínguez-González, C, Vissing, J, Richard, P, Metay, C, Khraiche, D, Wahbi, K, Stojkovic, T. Disease spectrum and long-term prognosis of patients with BAG3-associated neuromuscular diseases in Europe. BRAIN. 2025; DOI:10.1093/brain/awaf223. PMID:40493734. IF:11.700(Q1/1D).
08/11/2025
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Barnett-Tapia, C, Vicente, EC, Pascuzzi, RM, Utsugisawa, K, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study. JOURNAL OF NEUROLOGY. 2025; 272(12)DOI:10.1007/s00415-025-13480-8. PMID:41205003. IF:4.600(Q1/2D).
18/06/2025
Guía de recomendaciones para el diagnóstico y el tratamiento neurorrehabilitador de los estados secuelares pospoliomielíticos.
Povedano Pandés M, Rojas García R, Querol Gutiérrez L, Rodríguez de Rivera FJ, Colomer Font C, Noé Sebastián E, Navarro Pérez MD, Juárez Belaunde A, Ferri Campos J, Guijarro Castro TC. Guía de recomendaciones para el diagnóstico y el tratamiento neurorrehabilitador de los estados secuelares pospoliomielíticos.. Revista Espanola de Salud Publica. 2025; 99DOI:. PMID:40530649. IF:(Q/D).
29/01/2025
Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing
Lleixà, C, Titulaer, M, Rohrbacher, S, Mgbachi, V, Halstead, S, Fehmi, J, Pascual-Goñi, E, Zhu, L, Appeltshauser, L, Franken, S, Paunovic, M, Waters, P, Willison, H, Sommer, C, Querol, L, Huizinga, R, Doppler, K, Rinaldi, S. Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(1)DOI:10.1111/jns.70000. PMID:39887819. IF:3.200(Q2/4D).